Under the U.S.
Securities Act of 1933, as amended (the "Securities Act"), this
press release may be deemed to be offering material of Fresenius
Medical Care AG & Co. KGaA ("FME"). FME has filed a
registration statement on Form F-4 under the Securities Act
with the U.S. Securities and Exchange Commission (the "SEC"),
including an information statement/prospectus constituting a part
thereof. FME SHAREHOLDERS ARE URGED TO READ THE
REGISTRATION STATEMENT AND ANY OTHER RELEVANT DOCUMENTS FILED OR
THAT WILL BE FILED WITH THE SEC, INCLUDING THE INFORMATION
STATEMENT/PROSPECTUS THAT IS PART OF THE REGISTRATION
STATEMENT, AS THEY BECOME AVAILABLE, BECAUSE THEY CONTAIN OR WILL
CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED CONVERSION
DESCRIBED THEREIN. The final information
statement/prospectus has been distributed to FME shareholders.
Shareholders may obtain a free copy of the disclosure documents and
other documents filed by FME with the SEC at the SEC's website at
www.sec.gov or from Fresenius Medical Care AG & Co. KGaA,
Attention: Investor Relations, Else-Kröner-Straße 1, 61352 Bad
Homburg v.d.H., Germany.
|
WALTHAM,
Mass., July 10, 2023 /PRNewswire/ -- Fresenius
Medical Care, the world's leading provider of products and services
for individuals with renal diseases has appointed Martin Fischer (46) as Chief Financial Officer
as of October 1, 2023. He will
succeed Helen Giza who was appointed
as Chief Executive Officer and Chair of the Management Board in
December 2022 and continues to serve
as acting Chief Financial Officer, until her successor will join.
Martin Fischer will be based in Bad
Homburg, Germany and will assume
responsibility for the Global Finance Organization of Fresenius
Medical Care. Upon effectiveness of the Company's proposed change
of form from KGaA to German stock corporation, Martin Fischer will become a member of the
Management Board of Fresenius Medical Care AG.
Martin Fischer has been Head of
Finance for Siemens Healthineers Diagnostics Division based in
Tarrytown, NY, U.S. since 2019.
Previously, he headed the Board Office and Organizations function
for Siemens Healthineers after leading the business plan and
operating model development for the company's initial public
offering in March 2018. Prior to
that, Fischer held a number of key international operational and
finance positions in healthcare within Siemens AG. Martin Fischer holds a degree in business
informatics from the Reutlingen University of
Applied Sciences and an MBA from Friedrich Alexander
University in Nuremberg. He completed the Chief Financial Officer
Program at Columbia Business School in
New York, USA.
Michael Sen, Chairman of the
Supervisory Board of Fresenius Medical Care Management AG, says:
"With Martin Fischer's appointment, we are strengthening a vital
function in the Management Board of Fresenius Medical Care.
Martin Fischer has a deep
understanding of the international healthcare market, both from the
U.S. perspective and out of Germany. That's a decisive advantage in
getting the company back on track."
Helen Giza, CEO and Chair of the
Management Board, said: "Martin
Fischer has proven that he can successfully drive
fundamental change in organizations. In our organizational
transformation and turnaround management, we will benefit from his
finance and healthcare expertise. Martin will be an important
contributor to the execution of our strategy in unlocking value as
the leading kidney care company."
Martin Fischer said: "There are
great challenges ahead of us. I am convinced of the company's
potential and look forward to realizing it together with the global
team of Fresenius Medical Care. I am excited to bring my experience
and expertise to support the company's transformation."
Fresenius Medical Care is the world's leading provider of
products and services for individuals with renal diseases of which
around 3.9 million patients worldwide regularly undergo dialysis
treatment. Through its network of 4,060 dialysis clinics, Fresenius
Medical Care provides dialysis treatments for approximately 343,000
patients around the globe. Fresenius Medical Care is also the
leading provider of dialysis products such as dialysis machines or
dialyzers. Fresenius Medical Care is listed on the Frankfurt Stock
Exchange (FME) and on the New York Stock Exchange (FMS).
For more information visit the Company's website at
www.freseniusmedicalcare.com.
Disclaimer:
This release contains forward-looking statements that are subject
to various risks and uncertainties. Actual results could differ
materially from those described in these forward-looking statements
due to various factors, including, but not limited to, changes in
business, economic and competitive conditions, legal changes,
regulatory approvals, impacts related to the COVID-19 pandemic
results of clinical studies, foreign exchange rate fluctuations,
uncertainties in litigation or investigative proceedings, and the
availability of financing. These and other risks and uncertainties
are detailed in Fresenius Medical Care AG & Co. KGaA's reports
filed with the U.S. Securities and Exchange Commission. Fresenius
Medical Care AG & Co. KGaA does not undertake any
responsibility to update the forward-looking statements in this
release.
Media Contact
Steffen
Rinas
T +49 6172 608-6698
steffen.rinas@fresenius.com
Contact for analysts and investors
Dr. Dominik Heger
T +49 6172 609-2601
dominik.heger@fmc-ag.com
www.freseniusmedicalcare.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/fresenius-medical-care-appoints-martin-fischer-as-chief-financial-officer-301872913.html
SOURCE Fresenius Medical Care Holdings, Inc.